{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:27:59Z","timestamp":1770748079795,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00432-019-03012-z","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T11:02:51Z","timestamp":1567854171000},"page":"2495-2506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified"],"prefix":"10.1007","volume":"145","author":[{"given":"Takahiro","family":"Ota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-1826","authenticated-orcid":false,"given":"Keisuke","family":"Kirita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Matsuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hibiki","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Niho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genichiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,7]]},"reference":[{"key":"3012_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.currproblcancer.2017.02.003","volume":"41","author":"H Bando","year":"2017","unstructured":"Bando H (2017) The current status and problems confronted in delivering precision medicine in Japan and Europe. Curr Probl Cancer 41:166\u2013175. https:\/\/doi.org\/10.1016\/j.currproblcancer.2017.02.003","journal-title":"Curr Probl Cancer"},{"key":"3012_CR2","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/annonc\/mdu098","volume":"25","author":"F Barlesi","year":"2014","unstructured":"Barlesi F et al (2014) Maintenance bevacizumab\u2013pemetrexed after first-line cisplatin\u2013pemetrexed\u2013bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 25:1044\u20131052. https:\/\/doi.org\/10.1093\/annonc\/mdu098","journal-title":"Ann Oncol"},{"key":"3012_CR3","doi-asserted-by":"publisher","unstructured":"Comprehensive genomic characterization of squamous cell lung cancers (2012) Nature 489:519-525 https:\/\/doi.org\/10.1038\/nature11404","DOI":"10.1038\/nature11404"},{"key":"3012_CR4","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/jco.2008.17.2056","volume":"26","author":"LH Einhorn","year":"2008","unstructured":"Einhorn LH (2008) First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 26:3485\u20133486. https:\/\/doi.org\/10.1200\/jco.2008.17.2056","journal-title":"J Clin Oncol"},{"key":"3012_CR5","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1007\/s13277-015-3269-6","volume":"36","author":"F Facchinetti","year":"2015","unstructured":"Facchinetti F, Aldigeri R, Aloe R, Bortesi B, Ardizzoni A, Tiseo M (2015) CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients. Tumour Biol 36:5943\u20135951. https:\/\/doi.org\/10.1007\/s13277-015-3269-6","journal-title":"Tumour Biol"},{"key":"3012_CR6","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1002\/1097-0142(19940615)73:12<2936::AID-CNCR2820731210>3.0.CO;2-U","volume":"73","author":"NF Fishback","year":"1994","unstructured":"Fishback NF, Travis WD, Moran CA, Guinee DG Jr., McCarthy WF, Koss MN (1994) Pleomorphic (spindle\/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 73:2936\u20132945","journal-title":"Cancer"},{"key":"3012_CR7","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1200\/jco.2016.71.7629","volume":"35","author":"R Govindan","year":"2017","unstructured":"Govindan R et al (2017) Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol 35:3449\u20133457. https:\/\/doi.org\/10.1200\/jco.2016.71.7629","journal-title":"J Clin Oncol"},{"key":"3012_CR8","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1097\/JTO.0b013e318189f551","volume":"3","author":"FR Hirsch","year":"2008","unstructured":"Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M (2008) The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 3:1468\u20131481. https:\/\/doi.org\/10.1097\/JTO.0b013e318189f551","journal-title":"J Thorac Oncol"},{"key":"3012_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/jto.0b013e31815e8b60","volume":"3","author":"K Inamura","year":"2008","unstructured":"Inamura K et al (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3:13\u201317. https:\/\/doi.org\/10.1097\/jto.0b013e31815e8b60","journal-title":"J Thorac Oncol"},{"key":"3012_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/modpathol.2009.2","volume":"22","author":"K Inamura","year":"2009","unstructured":"Inamura K et al (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22:508\u2013515. https:\/\/doi.org\/10.1038\/modpathol.2009.2","journal-title":"Mod Pathol"},{"key":"3012_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/coc.0000000000000101","volume":"39","author":"Y Lin","year":"2016","unstructured":"Lin Y et al (2016) Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma. Am J Clin Oncol 39:215\u2013222. https:\/\/doi.org\/10.1097\/coc.0000000000000101","journal-title":"Am J Clin Oncol"},{"key":"3012_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1200\/jco.2005.08.043","volume":"23","author":"A Marchetti","year":"2005","unstructured":"Marchetti A et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J CLin Oncol 23:857\u2013865. https:\/\/doi.org\/10.1200\/jco.2005.08.043","journal-title":"J CLin Oncol"},{"key":"3012_CR13","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5:2892\u20132911","journal-title":"Am J Cancer Res"},{"key":"3012_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3892\/or.2011.1182","volume":"25","author":"Y Miyamae","year":"2011","unstructured":"Miyamae Y et al (2011) Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 25:921\u2013928. https:\/\/doi.org\/10.3892\/or.2011.1182","journal-title":"Oncol Rep"},{"key":"3012_CR15","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY) 304:1497\u20131500. https:\/\/doi.org\/10.1126\/science.1099314","journal-title":"Science (New York, NY)"},{"key":"3012_CR16","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W et al (2004) EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306\u201313311. https:\/\/doi.org\/10.1073\/pnas.0405220101","journal-title":"Proc Natl Acad Sci USA"},{"key":"3012_CR17","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1200\/jco.2012.47.9626","volume":"31","author":"JD Patel","year":"2013","unstructured":"Patel JD et al (2013) PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 31:4349\u20134357. https:\/\/doi.org\/10.1200\/jco.2012.47.9626","journal-title":"J Clin Oncol"},{"key":"3012_CR18","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/jco.2012.47.1102","volume":"31","author":"LG Paz-Ares","year":"2013","unstructured":"Paz-Ares LG et al (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895\u20132902. https:\/\/doi.org\/10.1200\/jco.2012.47.1102","journal-title":"J Clin Oncol"},{"key":"3012_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/1066896913511527","volume":"22","author":"G Pelosi","year":"2014","unstructured":"Pelosi G et al (2014) Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. Int J Surg Pathol 22:136\u2013148. https:\/\/doi.org\/10.1177\/1066896913511527","journal-title":"Int J Surg Pathol"},{"key":"3012_CR20","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/modpathol.2011.92","volume":"24","author":"N Rekhtman","year":"2011","unstructured":"Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL (2011) Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 24:1348\u20131359. https:\/\/doi.org\/10.1038\/modpathol.2011.92","journal-title":"Mod Pathol"},{"key":"3012_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/modpathol.2012.195","volume":"26","author":"N Rekhtman","year":"2013","unstructured":"Rekhtman N et al (2013) Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 26:511\u2013522. https:\/\/doi.org\/10.1038\/modpathol.2012.195","journal-title":"Mod Pathol"},{"key":"3012_CR22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1097\/jto.0000000000000271","volume":"9","author":"L Righi","year":"2014","unstructured":"Righi L et al (2014) Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. J Thorac Oncol 9:1540\u20131546. https:\/\/doi.org\/10.1097\/jto.0000000000000271","journal-title":"J Thorac Oncol"},{"key":"3012_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/JTO.0b013e3181fb7cd6","volume":"6","author":"M Salido","year":"2011","unstructured":"Salido M et al (2011) Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 6:21\u201327. https:\/\/doi.org\/10.1097\/JTO.0b013e3181fb7cd6","journal-title":"J Thorac Oncol"},{"key":"3012_CR24","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/jco.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543\u20133551. https:\/\/doi.org\/10.1200\/jco.2007.15.0375","journal-title":"J Clin Oncol"},{"key":"3012_CR25","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/cncr.23101","volume":"110","author":"F Shoji","year":"2007","unstructured":"Shoji F et al (2007) Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer 110:2793\u20132798. https:\/\/doi.org\/10.1002\/cncr.23101","journal-title":"Cancer"},{"key":"3012_CR26","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/s1470-2045(15)00305-8","volume":"16","author":"T Shukuya","year":"2015","unstructured":"Shukuya T et al (2015) Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol 16:1630\u20131638. https:\/\/doi.org\/10.1016\/s1470-2045(15)00305-8","journal-title":"Lancet Oncol"},{"key":"3012_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561\u2013566. https:\/\/doi.org\/10.1038\/nature05945","journal-title":"Nature"},{"key":"3012_CR28","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/jco.2009.27.1247","volume":"28","author":"TE Stinchcombe","year":"2010","unstructured":"Stinchcombe TE, Grilley-Olson JE, Socinski MA (2010) If histology matters. J Clin Oncol 28:1810\u20131812. https:\/\/doi.org\/10.1200\/jco.2009.27.1247","journal-title":"J Clin Oncol"},{"key":"3012_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603040","volume":"94","author":"K Sugio","year":"2006","unstructured":"Sugio K et al (2006) Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 94:896\u2013903. https:\/\/doi.org\/10.1038\/sj.bjc.6603040","journal-title":"Br J Cancer"},{"key":"3012_CR30","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1158\/1078-0432.ccr-08-1018","volume":"14","author":"K Takeuchi","year":"2008","unstructured":"Takeuchi K et al (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14:6618\u20136624. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-1018","journal-title":"Clin Cancer Res"},{"key":"3012_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.5858\/arpa.2012-0263-RA","volume":"137","author":"WD Travis","year":"2013","unstructured":"Travis WD et al (2013) Diagnosis of lung cancer in small biopsies and cytology: implications of the International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society classification. Arch Pathol Lab Med 137:668\u2013684. https:\/\/doi.org\/10.5858\/arpa.2012-0263-RA","journal-title":"Arch Pathol Lab Med"},{"key":"3012_CR32","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/jto.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD et al (2015) The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243\u20131260. https:\/\/doi.org\/10.1097\/jto.0000000000000630","journal-title":"J Thorac Oncol"},{"key":"3012_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/JTO.0b013e3181fd83a4","volume":"6","author":"MS Tsao","year":"2011","unstructured":"Tsao MS et al (2011) Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 6:139\u2013147. https:\/\/doi.org\/10.1097\/JTO.0b013e3181fd83a4","journal-title":"J Thorac Oncol"},{"key":"3012_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jtcvs.2007.05.031","volume":"134","author":"N Venissac","year":"2007","unstructured":"Venissac N, Pop D, Lassalle S, Berthier F, Hofman P, Mouroux J (2007) Sarcomatoid lung cancer (spindle\/giant cells): an aggressive disease? J Thorac Cardiovasc Surg 134:619\u2013623. https:\/\/doi.org\/10.1016\/j.jtcvs.2007.05.031","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3012_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5858\/arpa.2011-0232-oa","volume":"136","author":"K Whithaus","year":"2012","unstructured":"Whithaus K, Fukuoka J, Prihoda TJ, Jagirdar J (2012) Evaluation of napsin A, cytokeratin 5\/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med 136:155\u2013162. https:\/\/doi.org\/10.5858\/arpa.2011-0232-oa","journal-title":"Arch Pathol Lab Med"}],"updated-by":[{"DOI":"10.1007\/s00432-021-03737-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000}}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-019-03012-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T15:10:31Z","timestamp":1627053031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-019-03012-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,7]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3012"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-03012-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00432-021-03737-w","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,7]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00432-021-03737-w","URL":"https:\/\/doi.org\/10.1007\/s00432-021-03737-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Kirita reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chugai Pharmaceutical, personal fees from MSD, personal fees from Novartis Pharma, personal fees from Pfizer, personal fees from Roche, and personal fees from Boston, outside the submitted work. Dr. Udagawa reports personal fees from AstraZeneca, grants and personal fees from MSD, personal fees from Taiho, personal fees from Amco, grants and personal fees from AbbVie, personal fees from Chugai Pharmaceutical, personal fees from Bristol-Myers Squibb, personal fees from Ono Pharmaceutical, grants from Daiichi Sankyo, and grants from AMGEN, outside the submitted work. Dr. Matsumoto reports grants from Chugai Pharmaceutical Co., Ltd., grants from Novartis Pharma K.K., and grants from Merck Serono Co., Ltd., outside the submitted work. Dr. Yoh reports grants and personal fees from Ono Pharmaceutical, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Chugai Pharma, grants and personal fees from AstraZeneca, grants and personal fees from Lilly Japan, personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, grants from Pfizer, grants and personal fees from MSD, grants from Bristol-Myers Squibb, and grants from Bayer, outside the submitted work. Dr. Niho reports personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Chugai, grants and personal fees from AstraZeneca, grants from Merck Serono, and grants and personal fees from Pfizer, outside the submitted work. Dr. Goto reports grants and personal fees from Eli Lilly, during the conduct of the study; grants and personal fees from AbbVie Stemcentrx, grants from Ignyta, personal fees from F. Hoffmann-La Roche, grants and personal fees from Life Technologies Japan, grants from Oxonc, personal fees from Otsuka Pharmaceutical, grants and personal fees from RIKEN GENESIS, personal fees from SRL, grants and personal fees from Sumitomo Dainippon Pharma, grants and personal fees from AstraZeneca, grants from Astellas Pharma, grants from Amgen Astellas BioPharma, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Daiichi Sankyo, grants from Eisai, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from MSD, grants and personal fees from Merck Serono, grants and personal fees from Novartis Pharma, grants and personal fees from ONO Pharmaceutical, grants and personal fees from Pfizer, grants and personal fees from Taiho, grants and personal fees from Takeda Pharmaceutical, and grants from Janssen Pharmaceutical, outside the submitted work. None of the other authors has any conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted with the approval of the Institutional Review Boards of the National Cancer Center. The IRB approval number for this study was 2016-125. All the methods were performed in accordance with the approved guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the specimens were collected after obtaining written comprehensive informed consent from the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}